Donafenib (Sorafenib D3)

Donafenib (Sorafenib D3, Bay 43-9006 D3, CM-4307)是氘标记的Sorafenib。Sorafenib 是一种多激酶的抑制剂，对 Raf-1、mVEGFR-2、mVEGFR-3 和 B-RAF 的抑制作用对应的IC50值分别为6 nM、15 nM、20 nM和22 nM。 Information Donafenib (Sorafenib D3, Bay 43-9006 D3, CM-4307) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 15 nM, 20 nM and 22 nM forRaf-1,mVEGFR-2,mVEGFR-3andB-RAF, respectively. Targets Raf-1 (Cell-free assay); mVEGFR-2 (Cell-free assay); mVEGFR-3 (Cell-free assay); B-Raf (Cell-free assay) 6 nM; 15 nM; 20 nM; 22 nM In vitro BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro. In addition, BAY 43-9006 demonstrates significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor β, Flt-3, and c-KIT. In cellular mechanistic assays, BAY 43-9006 demonstrates inhibition of the mitogen-activated protein kinase pathway in colon, pancreatic, and breast tumor cell lines expressing mutant KRAS or wild-type or mutant BRAF, whereas non–small-cell lung cancer cell lines expressing mutant KRAS are insensitive to inhibition of the mitogen-activated protein kinase pathway by BAY 43-9006. Potent inhibition of VEGFR-2, platelet-derived growth factor receptor β, and VEGFR-3 cellular receptor autophosphorylation is also observed for BAY 43-9006. In vivo Once daily oral dosing of BAY 43-9006 demonstrates broad-spectrum antitumor activity in colon, breast, and non–small-cell lung cancer xenograft models. Immunohistochemistry demonstrates a close association between inhibition of tumor growth and inhibition of the extracellular signal-regulated kinases (ERKs) 1/2 phosphorylation in two of three xenograft models examined, consistent with inhibition of the RAF/MEK/ERK pathway in some but not all models. Additional analyses of microvessel density and microvessel area in the same tumor sections using antimurine CD31 antibodies demonstrates significant inhibition of neovascularization in all three of the xenograft models. Cell Research(from reference) Cell lines：MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, A549 cell lines Concentrations：0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM Incubation Time：120 min

No numbering system information yet

No physical and chemical property information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet